Wyeth and Elan's shares were up today as the companies announced potentially promising results from a phase II trial of bapineuzumab, an Alzheimer's treatment. The study did not attain statistical significance on the efficacy endpoints in the overall study population, but the vaccine helped patients without a gene known as ApoE4. About 70 percent of Alzheimer's sufferers don't have the ApoE4 gene. A spokesperson for the company said the results support the decision to move bapineuzumab into Phase III trials.
- see this release for more